Company intelligence / Profile preview
Cyta Therapeutics
Boston, Massachusetts, United Statescytatx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Cyta’s lead candidate, a liver-targeted nanoparticle encapsulating a thyromimetic drug, has shown promising preclinical results in mouse models of obesity and NASH. The candidate demonstrated 28% weight loss, reduced cholesterol and triglycerides, improved insulin sensitivity, and reduced fatty liver without peripheral side effects or safety concerns in short-term toxicity studies. IND submission is projected within two years as of mid–2023[5].
- Therapeutic areas
- GastroenterologyEndocrinologyCardiovascular
- Modalities
- Polymer-based nanogels (IntelliGels)Small molecules (thyromimetic drugs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Exclusive option to platform technology developed at University of Massachusetts Amherst by Prof. S. Thayumanavan’s lab[1][5]
Beyond the preview
Go deeper on Cyta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyta Therapeutics.